FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
International journal of molecular sciences2020; 21(4); 1453; doi: 10.3390/ijms21041453

Effects of Orally Administered Resveratrol on TNF, IL-1β, Leukocyte Phagocytic Activity and Oxidative Burst Function in Horses: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study.

Abstract: Resveratrol, a phytophenol, is a commonly used equine nutraceutical supplement touted to exert anti-inflammatory effects. The effect of orally administered resveratrol on tumor necrosis factor (TNF), interleukin-1β (IL-1β), leukocyte phagocytic activity or oxidative burst function have not been reported in horses. The objective of this study was to determine the effects of a commercially available, orally administered resveratrol product on innate immune functions in healthy adult horses. Whole blood was collected from 12 horses prior to and following 3 weeks of treatment with either the manufacturer's recommended dose of resveratrol or placebo. Phagocytosis, oxidative burst and pathogen associated molecular pattern (PAMP) motif-stimulated leukocyte production of TNF and IL-1β were compared pre- and post-treatment between treatment groups. Phagocytosis and oxidative burst capacity were evaluated via flow cytometry. Tumor necrosis factor and IL-1β were measured using cytotoxicity and ELISA assays, respectively. There were no significant differences in phagocytosis, oxidative burst or stimulated TNF or IL-1β production between resveratrol and placebo treatment groups. Orally administered resveratrol at a routinely recommended dose for a duration of 3 weeks did not significantly affect phagocytic activity, oxidative burst function or PAMP-stimulated leukocyte cytokine production.
Get Full Text
Publication Date: 2020-02-20 PubMed ID: 32093379PubMed Central: PMC7073105DOI: 10.3390/ijms21041453Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Veterinary

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study aimed to identify the effects of using a commercially available resveratrol product, known for its anti-inflammatory attributes, on the innate immune functions in healthy horses. It was found that administering the product orally for three weeks had no significant impact on phagocytic activity, oxidative burst function, or cytokine production.

Objective of the Study

  • The main aim of the study was to examine the influence of orally administered resveratrol on innate immune functions in healthy adult horses. The focus was predominantly on how resveratrol might affect tumor necrosis factor (TNF), interleukin-1β (IL-1β), leukocyte phagocytic activity or oxidative burst function.

Methodology of the Study

  • 12 horses participated in this study. Blood samples were collected from these horses before and after a three-week treatment period.
  • The horses were given treatment with either the resveratrol product or a placebo at the manufacturer’s recommended dosage.
  • Phagocytosis, the ability of a cell to engulf particles or bacteria, and oxidative burst, a rapid release of reactive oxygen species from different types of cells, were measured through flow cytometry.
  • The levels of TNF-a protein involved in systemic inflammation-and IL-1β-a group of cytokines that play important roles in the regulation of immune and inflammatory responses were measured using cytotoxicity and ELISA assays respectively.

Results of the Study

  • The results showed no significant differences between the group treated with resveratrol and the placebo group, in terms of phagocytosis, oxidative burst, and TNF and IL-1β production.
  • The study concluded that oral administration of resveratrol at the manufacturer-recommended dose for a duration of three weeks had no impact on phagocytic activity, oxidative burst function or the production of cytokines in response to pathogen associated molecular pattern (PAMP) stimulation in leukocytes.

Implications of the Study

  • The outcomes of this study challenge the common perception of resveratrol’s potential to exert anti-inflammatory effects. It suggests that longer-term or higher dosage may be needed to see significant effects, if there are any, in horses.
  • This research can help inform decisions around the utilization and effectiveness of resveratrol as a supplement for horses, leading to better health and care practices for these animals.

Cite This Article

APA
Martin LM, Johnson PJ, Amorim JR, DeClue AE. (2020). Effects of Orally Administered Resveratrol on TNF, IL-1β, Leukocyte Phagocytic Activity and Oxidative Burst Function in Horses: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study. Int J Mol Sci, 21(4), 1453. https://doi.org/10.3390/ijms21041453

Publication

International journal of molecular sciences
ISSN: 1422-0067
NlmUniqueID: 101092791
Country: Switzerland
Language: English
Volume: 21
Issue: 4
PII: 1453

Researcher Affiliations

Martin, Lynn M
  • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 900 East Campus Drive, Columbia, MO 65211, USA.
Johnson, Philip J
  • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 900 East Campus Drive, Columbia, MO 65211, USA.
Amorim, Juliana R
  • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 900 East Campus Drive, Columbia, MO 65211, USA.
DeClue, Amy E
  • Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, 900 East Campus Drive, Columbia, MO 65211, USA.

MeSH Terms

  • Administration, Oral
  • Animals
  • Double-Blind Method
  • Horses
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammation / pathology
  • Inflammation / veterinary
  • Interleukin-1beta / adverse effects
  • Interleukin-1beta / immunology
  • Leukocytes / immunology
  • Phagocytosis / drug effects
  • Prospective Studies
  • Respiratory Burst / drug effects
  • Resveratrol / pharmacology
  • Tumor Necrosis Factor-alpha / immunology

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 71 references
  1. Doucet MY, Bertone AL, Hendrickson D, Hughes F, Macallister C, McClure S, Reinemeyer C, Rossier Y, Sifferman R, Vrins AA, White G, Kunkle B, Alva R, Romano D, Hanson PD. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.. J Am Vet Med Assoc 2008 Jan 1;232(1):91-7.
    doi: 10.2460/javma.232.1.91pubmed: 18167116google scholar: lookup
  2. Hu HH, MacAllister CG, Payton ME, Erkert RS. Evaluation of the analgesic effects of phenylbutazone administered at a high or low dosage in horses with chronic lameness.. J Am Vet Med Assoc 2005 Feb 1;226(3):414-7.
    doi: 10.2460/javma.2005.226.414pubmed: 15702692google scholar: lookup
  3. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.. J Intern Med 2003 Jun;253(6):643-52.
    doi: 10.1046/j.1365-2796.2003.01146.xpubmed: 12755960google scholar: lookup
  4. Nieto JE, Aleman M, Anderson JD, Fiack C, Snyder JR. Effects of phenylbutazone on gene expression of cyclooxygenase-1 and -2 in the oral, glandular gastric, and bladder mucosae of healthy horses.. Am J Vet Res 2012 Jan;73(1):98-104.
    doi: 10.2460/ajvr.73.1.98pubmed: 22204294google scholar: lookup
  5. Knych HK, Corado CR, McKemie DS, Steffey EP. Pharmacokinetics and selected pharmacodynamic effects of tramadol following intravenous administration to the horse.. Equine Vet J 2013 Jul;45(4):490-6.
    doi: 10.1111/j.2042-3306.2012.00688.xpubmed: 23145962google scholar: lookup
  6. Shilo Y, Britzi M, Eytan B, Lifschitz T, Soback S, Steinman A. Pharmacokinetics of tramadol in horses after intravenous, intramuscular and oral administration.. J Vet Pharmacol Ther 2008 Feb;31(1):60-5.
    doi: 10.1111/j.1365-2885.2007.00929.xpubmed: 18177320google scholar: lookup
  7. Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: A review.. Crit Rev Food Sci Nutr 2018 Jun 13;58(9):1428-1447.
    doi: 10.1080/10408398.2016.1263597pubmed: 28001084google scholar: lookup
  8. Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, Gupta SC. Health benefits of resveratrol: Evidence from clinical studies.. Med Res Rev 2019 Sep;39(5):1851-1891.
    doi: 10.1002/med.21565pubmed: 30741437google scholar: lookup
  9. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence.. Nat Rev Drug Discov 2006 Jun;5(6):493-506.
    doi: 10.1038/nrd2060pubmed: 16732220google scholar: lookup
  10. Cianciulli A, Dragone T, Calvello R, Porro C, Trotta T, Lofrumento DD, Panaro MA. IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells.. Int Immunopharmacol 2015 Feb;24(2):369-376.
    doi: 10.1016/j.intimp.2014.12.035pubmed: 25576658google scholar: lookup
  11. Diaz-Gerevini GT, Repossi G, Dain A, Tarres MC, Das UN, Eynard AR. Beneficial action of resveratrol: How and why?. Nutrition 2016 Feb;32(2):174-8.
    doi: 10.1016/j.nut.2015.08.017pubmed: 26706021google scholar: lookup
  12. Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans.. Biochim Biophys Acta 2015 Jun;1852(6):1071-113.
    doi: 10.1016/j.bbadis.2015.01.014pubmed: 25652123google scholar: lookup
  13. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health--a comprehensive review of human clinical trials.. Mol Nutr Food Res 2011 Aug;55(8):1129-41.
    doi: 10.1002/mnfr.201100143pubmed: 21688389google scholar: lookup
  14. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol.. PLoS One 2011;6(6):e19881.
    doi: 10.1371/journal.pone.0019881pmc: PMC3116821pubmed: 21698226google scholar: lookup
  15. Beijers RJHCG, Gosker HR, Schols AMWJ. Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?. Curr Opin Clin Nutr Metab Care 2018 Mar;21(2):138-144.
    doi: 10.1097/MCO.0000000000000444pmc: PMC5811233pubmed: 29200030google scholar: lookup
  16. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, Shu F, Gao Y, Yuan L, Zhang Q, Mi M. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.. Dig Liver Dis 2015 Mar;47(3):226-32.
    doi: 10.1016/j.dld.2014.11.015pubmed: 25577300google scholar: lookup
  17. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease.. Ann N Y Acad Sci 2011 Jan;1215:117-22.
    doi: 10.1111/j.1749-6632.2010.05848.xpmc: PMC3058481pubmed: 21261649google scholar: lookup
  18. Javid AZ, Hormoznejad R, Yousefimanesh HA, Haghighi-Zadeh MH, Zakerkish M. Impact of resveratrol supplementation on inflammatory, antioxidant, and periodontal markers in type 2 diabetic patients with chronic periodontitis.. Diabetes Metab Syndr 2019 Jul-Aug;13(4):2769-2774.
    pubmed: 31405706doi: 10.1016/j.dsx.2019.07.042google scholar: lookup
  19. Samsami-Kor M, Daryani NE, Asl PR, Hekmatdoost A. Anti-Inflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study.. Arch Med Res 2015 May;46(4):280-5.
    doi: 10.1016/j.arcmed.2015.05.005pubmed: 26002728google scholar: lookup
  20. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, Durazzo M, Cavallo-Perin P, Cassader M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial.. Curr Med Chem 2013;20(10):1323-31.
    doi: 10.2174/0929867311320100009pubmed: 23298135google scholar: lookup
  21. Silva AM, Oliveira MI, Sette L, Almeida CR, Oliveira MJ, Barbosa MA, Santos SG. Resveratrol as a natural anti-tumor necrosis factor-α molecule: implications to dendritic cells and their crosstalk with mesenchymal stromal cells.. PLoS One 2014;9(3):e91406.
    pmc: PMC3948844pubmed: 24614867doi: 10.1371/journal.pone.0091406google scholar: lookup
  22. Kumar A, Sharma SS. NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy.. Biochem Biophys Res Commun 2010 Apr 2;394(2):360-5.
    doi: 10.1016/j.bbrc.2010.03.014pubmed: 20211601google scholar: lookup
  23. Adams A, Siard M, Reedy S, Stewart C, Betancourt A, Sanz M, Horohov D. Identifying the role of a “caloric restriction mimetic”, resveratrol, in Equine Metabolic Syndrome and its implications for targeted therapy.. J. Equine Veter. Sci. 2013;33:346–347.
    doi: 10.1016/j.jevs.2013.03.064google scholar: lookup
  24. Ememe M.U, Mshelia P, Ayo J.O. Ameliorative Effects of Resveratrol on Oxidative Stress Biomarkers in Horses.. J. Equine Veter. Sci. 2015;35:518–523.
    doi: 10.1016/j.jevs.2015.02.006google scholar: lookup
  25. Ememe MU, Abdullahi US, Sackey AK, Ayo JO, Mshelia WP, Edeh RE. Effects of a joint supplement whose main components are resveratrol and hyaluronic acid on some biochemical parameters in aged lame horses.. J Equine Sci 2016;27(1):19-22.
    doi: 10.1294/jes.27.19pmc: PMC4828249pubmed: 27073333google scholar: lookup
  26. Ememe M, Edeh E, Abdullahi U.S, Sackey A.K.B, Ayo J.O. Changes in hematological parameters and erythrocyte osmotic fragility in lame and aged horses administered with resveratrol supplement.. Afr. J. Biomed. Res. 2016;19:37–43.
  27. Kohlhaas K.S. Effects of Resveratrol Supplementation on Metabolic Health and Reproductive Performance in Obese Mares on Pasture.. Apr 26, 2013.
  28. Watts AE, Dabareiner R, Marsh C, Carter GK, Cummings KJ. A randomized, controlled trial of the effects of resveratrol administration in performance horses with lameness localized to the distal tarsal joints.. J Am Vet Med Assoc 2016 Sep 15;249(6):650-9.
    doi: 10.2460/javma.249.6.650pubmed: 27585103google scholar: lookup
  29. Zambito J.L. Effects of Resveratrol Supplementation on Glycemic Response and Oxidant Status in Moderately Exercised Mature Quarter Horse Geldings.. 2011.
  30. Frank N, Geor RJ, Bailey SR, Durham AE, Johnson PJ. Equine metabolic syndrome.. J Vet Intern Med 2010 May-Jun;24(3):467-75.
    doi: 10.1111/j.1939-1676.2010.0503.xpubmed: 20384947google scholar: lookup
  31. Durham AE, Frank N, McGowan CM, Menzies-Gow NJ, Roelfsema E, Vervuert I, Feige K, Fey K. ECEIM consensus statement on equine metabolic syndrome.. J Vet Intern Med 2019 Mar;33(2):335-349.
    doi: 10.1111/jvim.15423pmc: PMC6430910pubmed: 30724412google scholar: lookup
  32. Martin LM, Johnson PJ, Amorim JR, Honaker AR, Donaldson RS, DeClue AE. Investigation of the potential immunomodulatory effects of resveratrol on equine whole blood: An in vitro investigation.. Res Vet Sci 2016 Jun;106:97-9.
    doi: 10.1016/j.rvsc.2016.03.015pubmed: 27234544google scholar: lookup
  33. Siard MH, McMurry KE, Adams AA. Effects of polyphenols including curcuminoids, resveratrol, quercetin, pterostilbene, and hydroxypterostilbene on lymphocyte pro-inflammatory cytokine production of senior horses in vitro.. Vet Immunol Immunopathol 2016 May;173:50-9.
    doi: 10.1016/j.vetimm.2016.04.001pubmed: 27090627google scholar: lookup
  34. Mathew LM, Woode RA, Axiak-Bechtel SM, Amorim JR, DeClue AE. Resveratrol administration increases phagocytosis, decreases oxidative burst, and promotes pro-inflammatory cytokine production in healthy dogs.. Vet Immunol Immunopathol 2018 Sep;203:21-29.
    doi: 10.1016/j.vetimm.2018.07.013pubmed: 30243369google scholar: lookup
  35. Sheats MK. A Comparative Review of Equine SIRS, Sepsis, and Neutrophils.. Front Vet Sci 2019;6:69.
    doi: 10.3389/fvets.2019.00069pmc: PMC6424004pubmed: 30931316google scholar: lookup
  36. Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N, Sharifi-Rad J. Resveratrol: A Double-Edged Sword in Health Benefits.. Biomedicines 2018 Sep 9;6(3).
    doi: 10.3390/biomedicines6030091pmc: PMC6164842pubmed: 30205595google scholar: lookup
  37. Walle T. Bioavailability of resveratrol.. Ann N Y Acad Sci 2011 Jan;1215:9-15.
    doi: 10.1111/j.1749-6632.2010.05842.xpubmed: 21261636google scholar: lookup
  38. Bode LM, Bunzel D, Huch M, Cho GS, Ruhland D, Bunzel M, Bub A, Franz CM, Kulling SE. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota.. Am J Clin Nutr 2013 Feb;97(2):295-309.
    doi: 10.3945/ajcn.112.049379pubmed: 23283496google scholar: lookup
  39. Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study.. Cancer Prev Res (Phila) 2010 Sep;3(9):1168-75.
    doi: 10.1158/1940-6207.CAPR-09-0155pmc: PMC2933312pubmed: 20716633google scholar: lookup
  40. Ericsson AC, Johnson PJ, Lopes MA, Perry SC, Lanter HR. A Microbiological Map of the Healthy Equine Gastrointestinal Tract.. PLoS One 2016;11(11):e0166523.
    doi: 10.1371/journal.pone.0166523pmc: PMC5112786pubmed: 27846295google scholar: lookup
  41. Muzzio M, Huang Z, Hu SC, Johnson WD, McCormick DL, Kapetanovic IM. Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs.. J Pharm Biomed Anal 2012 Feb 5;59:201-8.
    doi: 10.1016/j.jpba.2011.10.023pmc: PMC3235727pubmed: 22079044google scholar: lookup
  42. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.. Cancer Epidemiol Biomarkers Prev 2007 Jun;16(6):1246-52.
    doi: 10.1158/1055-9965.EPI-07-0022pubmed: 17548692google scholar: lookup
  43. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis.. Cancer Res 2010 Nov 15;70(22):9003-11.
    doi: 10.1158/0008-5472.CAN-10-2364pmc: PMC2982884pubmed: 20935227google scholar: lookup
  44. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity.. Toxicol Sci 2004 Dec;82(2):614-9.
    doi: 10.1093/toxsci/kfh263pubmed: 15329443google scholar: lookup
  45. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span.. Cell Metab 2008 Aug;8(2):157-68.
    doi: 10.1016/j.cmet.2008.06.011pmc: PMC2538685pubmed: 18599363google scholar: lookup
  46. Swirsley N, Spooner H.S, Hoffman R.M. Supplement Use and Perceptions: A Study of US Horse Owners.. J. Equine Veter. Sci. 2017;59:34–39.
    doi: 10.1016/j.jevs.2017.08.021google scholar: lookup
  47. Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability.. Free Radic Biol Med 2002 Aug 1;33(3):387-98.
    doi: 10.1016/S0891-5849(02)00911-5pubmed: 12126761google scholar: lookup
  48. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats.. Cancer Chemother Pharmacol 2011 Sep;68(3):593-601.
    doi: 10.1007/s00280-010-1525-4pmc: PMC3090701pubmed: 21116625google scholar: lookup
  49. Masterson GR, Hunter JM. Does anaesthesia have long-term consequences?. Br J Anaesth 1996 Nov;77(5):569-71.
    doi: 10.1093/bja/77.5.569pubmed: 8957968google scholar: lookup
  50. Roth-Isigkeit A, Hasselbach L, Ocklitz E, Brückner S, Ros A, Gehring H, Schmucker P, Rink L, Seyfarth M. Inter-individual differences in cytokine release in patients undergoing cardiac surgery with cardiopulmonary bypass.. Clin Exp Immunol 2001 Jul;125(1):80-8.
    doi: 10.1046/j.1365-2249.2001.01521.xpmc: PMC1906109pubmed: 11472429google scholar: lookup
  51. Schraut W, Wendelgass P, Calzada-Wack JC, Frankenberger M, Ziegler-Heitbrock HW. TNF gene expression in monocytes of low and high responder individuals.. Cytokine 1997 Mar;9(3):206-11.
    doi: 10.1006/cyto.1996.0155pubmed: 9126709google scholar: lookup
  52. Gurgul A, Jasielczuk I, Semik-Gurgul E, Pawlina-Tyszko K, Stefaniuk-Szmukier M, Szmatoła T, Polak G, Tomczyk-Wrona I, Bugno-Poniewierska M. A genome-wide scan for diversifying selection signatures in selected horse breeds.. PLoS One 2019;14(1):e0210751.
    doi: 10.1371/journal.pone.0210751pmc: PMC6353161pubmed: 30699152google scholar: lookup
  53. Fredman NJ, Duque G, Duckham RL, Green D, Brennan-Olsen SL. Associations between socioeconomic factors and proinflammatory cytokines in children, adolescents and young adults: a systematic review protocol.. BMJ Open 2018 Feb 28;8(2):e019381.
    doi: 10.1136/bmjopen-2017-019381pmc: PMC5855348pubmed: 29490962google scholar: lookup
  54. Li Y, Oosting M, Smeekens SP, Jaeger M, Aguirre-Gamboa R, Le KTT, Deelen P, Ricaño-Ponce I, Schoffelen T, Jansen AFM, Swertz MA, Withoff S, van de Vosse E, van Deuren M, van de Veerdonk F, Zhernakova A, van der Meer JWM, Xavier RJ, Franke L, Joosten LAB, Wijmenga C, Kumar V, Netea MG. A Functional Genomics Approach to Understand Variation in Cytokine Production in Humans.. Cell 2016 Nov 3;167(4):1099-1110.e14.
    doi: 10.1016/j.cell.2016.10.017pubmed: 27814507google scholar: lookup
  55. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines.. ISRN Inflamm 2013 Dec 22;2013:139239.
    doi: 10.1155/2013/139239pmc: PMC3881510pubmed: 24455420google scholar: lookup
  56. Moldoveanu AI, Shephard RJ, Shek PN. The cytokine response to physical activity and training.. Sports Med 2001 Feb;31(2):115-44.
    doi: 10.2165/00007256-200131020-00004pmc: PMC7101891pubmed: 11227979google scholar: lookup
  57. Schirmer M, Kumar V, Netea MG, Xavier RJ. The causes and consequences of variation in human cytokine production in health.. Curr Opin Immunol 2018 Oct;54:50-58.
    doi: 10.1016/j.coi.2018.05.012pubmed: 29913309google scholar: lookup
  58. Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, Kumar V, Diavatopoulos DA, Jansen AFM, Lemmers H, Toenhake-Dijkstra H, van Herwaarden AE, Janssen M, van der Molen RG, Joosten I, Sweep FCGJ, Smit JW, Netea-Maier RT, Koenders MMJF, Xavier RJ, van der Meer JWM, Dinarello CA, Pavelka N, Wijmenga C, Notebaart RA, Joosten LAB, Netea MG. Host and Environmental Factors Influencing Individual Human Cytokine Responses.. Cell 2016 Nov 3;167(4):1111-1124.e13.
    doi: 10.1016/j.cell.2016.10.018pmc: PMC5787854pubmed: 27814508google scholar: lookup
  59. Funk RA, Stewart AJ, Wooldridge AA, Kwessi E, Kemppainen RJ, Behrend EN, Zhong Q, Johnson AK. Seasonal changes in plasma adrenocorticotropic hormone and α-melanocyte-stimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses.. J Vet Intern Med 2011 May-Jun;25(3):579-85.
    doi: 10.1111/j.1939-1676.2011.0712.xpubmed: 21457320google scholar: lookup
  60. Borer-Weir KE, Menzies-Gow NJ, Bailey SR, Harris PA, Elliott J. Seasonal and annual influence on insulin and cortisol results from overnight dexamethasone suppression tests in normal ponies and ponies predisposed to laminitis.. Equine Vet J 2013 Nov;45(6):688-93.
    doi: 10.1111/evj.12053pubmed: 23521139google scholar: lookup
  61. Benbarek H, Deby-Dupont G, Caudron I, Grülke S, Deby C, Lamy M, Serteyn D. Interactions between lipopolysaccharides and blood factors on the stimulation of equine polymorphonuclear neutrophils.. Vet Immunol Immunopathol 1998 Aug 31;64(4):313-22.
    doi: 10.1016/S0165-2427(98)00142-1pubmed: 9764724google scholar: lookup
  62. Damsgaard CT, Lauritzen L, Calder PC, Kjaer TM, Frøkiaer H. Whole-blood culture is a valid low-cost method to measure monocytic cytokines - a comparison of cytokine production in cultures of human whole-blood, mononuclear cells and monocytes.. J Immunol Methods 2009 Jan 30;340(2):95-101.
    doi: 10.1016/j.jim.2008.10.005pubmed: 19000693google scholar: lookup
  63. De Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, Dehart I. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.. Cytokine 1992 May;4(3):239-48.
    doi: 10.1016/1043-4666(92)90062-Vpubmed: 1498259google scholar: lookup
  64. Declue AE, Johnson PJ, Day JL, Amorim JR, Honaker AR. Pathogen associated molecular pattern motifs from Gram-positive and Gram-negative bacteria induce different inflammatory mediator profiles in equine blood.. Vet J 2012 Jun;192(3):455-60.
    doi: 10.1016/j.tvjl.2011.09.001pubmed: 21974971google scholar: lookup
  65. Baarsch MJ, Wannemuehler MJ, Molitor TW, Murtaugh MP. Detection of tumor necrosis factor alpha from porcine alveolar macrophages using an L929 fibroblast bioassay.. J Immunol Methods 1991 Jun 24;140(1):15-22.
    doi: 10.1016/0022-1759(91)90121-Upubmed: 1712031google scholar: lookup
  66. DeClue AE, Cohn LA, Lechner ES, Bryan ME, Dodam JR. Effects of subanesthetic doses of ketamine on hemodynamic and immunologic variables in dogs with experimentally induced endotoxemia.. Am J Vet Res 2008 Feb;69(2):228-32.
    doi: 10.2460/ajvr.69.2.228pubmed: 18241020google scholar: lookup
  67. DeClue AE, Williams KJ, Sharp C, Haak C, Lechner E, Reinero CR. Systemic response to low-dose endotoxin infusion in cats.. Vet Immunol Immunopathol 2009 Dec 15;132(2-4):167-74.
    doi: 10.1016/j.vetimm.2009.06.002pubmed: 19577810google scholar: lookup
  68. Nafe LA, DeClue AE, Lee-Fowler TM, Eberhardt JM, Reinero CR. Evaluation of biomarkers in bronchoalveolar lavage fluid for discrimination between asthma and chronic bronchitis in cats.. Am J Vet Res 2010 May;71(5):583-91.
    doi: 10.2460/ajvr.71.5.583pubmed: 20433386google scholar: lookup
  69. Suagee JK, Corl BA, Crisman MV, Pleasant RS, Thatcher CD, Geor RJ. Relationships between body condition score and plasma inflammatory cytokines, insulin, and lipids in a mixed population of light-breed horses.. J Vet Intern Med 2013 Jan-Feb;27(1):157-63.
    doi: 10.1111/jvim.12021pubmed: 23216530google scholar: lookup
  70. Mateus L, Lopes da Costa L, Carvalho H, Serra P, Robalo Silva J. Blood and intrauterine leukocyte profile and function in dairy cows that spontaneously recovered from postpartum endometritis.. Reprod Domest Anim 2002 Jun;37(3):176-80.
    doi: 10.1046/j.1439-0531.2002.00351.xpubmed: 12071893google scholar: lookup
  71. Roberto Da Costa RP, Carvalho H, Agrícola R, Alpoim-Moreira J, Martins C, Ferreira-Dias G. Peripheral blood neutrophil function and lymphocyte subpopulations in cycling mares.. Reprod Domest Anim 2003 Dec;38(6):464-9.
    doi: 10.1046/j.0936-6768.2003.00464.xpubmed: 14629669google scholar: lookup

Citations

This article has been cited 4 times.
  1. McBride MA, Owen AM, Stothers CL, Hernandez A, Luan L, Burelbach KR, Patil TK, Bohannon JK, Sherwood ER, Patil NK. The Metabolic Basis of Immune Dysfunction Following Sepsis and Trauma. Front Immunol 2020;11:1043.
    doi: 10.3389/fimmu.2020.01043pubmed: 32547553google scholar: lookup
  2. Schimith LE, Martis E, Teletchea S, Muccillo-Baisch AL, André-Miral C, Hort MA. Glycosylation Matters: Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol Glycosylated Derivatives on Parkinson's Disease. ACS Omega 2026 Feb 10;11(5):7597-7615.
    doi: 10.1021/acsomega.5c08887pubmed: 41696202google scholar: lookup
  3. Rintz E, Podlacha M, Gaffke L, Jerzemowska G, Cyske Z, Pierzynowska K, Węgrzyn G. TFEB, FOXO3 and TLR4 in resveratrol-induced autophagy in a mucopolysaccharidosis IIIB mouse model. Exp Mol Med 2026 Feb 5;.
    doi: 10.1038/s12276-026-01643-0pubmed: 41639426google scholar: lookup
  4. Giercuszkiewicz-Hecold B, Kulka M, Czopowicz M, Szarska E, Strzelec K, Grzeczka A, Graczyk S, Wiśniewska M, Jędrzejkowska Z, Rumińska A, Marycz K, Cywińska A. Astaxanthin Supplementation Does Not Alter Training-Related Changes in Inflammatory Cytokine Profile in Arabian Racing Horses. Antioxidants (Basel) 2024 Jul 26;13(8).
    doi: 10.3390/antiox13080905pubmed: 39199150google scholar: lookup
Subscribe to our newsletter
Join 99,970 horse owners like you who receive our email updates on horse health and nutrition.